Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M V Mateos

Showing results (21-30 of 72) with videos related to

Pageof 8
Sort By:
Hematological Oncology|September 29, 2006
Pegylated liposomal doxorubicin, melphalan and prednisone therapy for elderly patients with multiple myelomaR García-Sanz, J M Hernández, A Sureda, et al.
Clinical Biochemistry|October 6, 2000
Status of methylation of p16 gene in multiple myeloma: a comparative study of three methods for its detectionM V Mateos, M González, A Balanzategui, et al.
Leukemia|December 20, 2017
Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyondC S Chim, S K Kumar, R Z Orlowski, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Inverse Probability of Censoring Weighted Analysis to Adjust the Treatment Effect on Overall Survival for Subsequent Therapy: A Case Study in a Clinical Trial in Multiple MyelomaP Thilakarathne, A Palumbo, J Diels, et al.
Leukemia|March 8, 2019
Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyondC S Chim, S K Kumar, R Z Orlowski, et al.
Haematologica|June 15, 1999
Hematopoietic damage prior to PBSCT and its influence on hematopoietic recoveryM C del Cañizo, N Lopez, L Vazquez, et al.
Thrombosis Research|September 29, 2006
Hyperhomocysteinemia is a risk factor of recurrent coronary event in young patients irrespective to the MTHFR C677T polymorphismJ R Gonzalez-Porras, F Martin-Herrero, R Garcia-Sanz, et al.
Leukemia|July 30, 2002
Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantationJ A Pérez-Simón, D Caballero, M Diez-Campelo, et al.
Bone Marrow Transplantation|March 14, 2003
Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioningD Valcárcel, R Martino, D Caballero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 1998
Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemiaJ Ciudad, J F San Miguel, M C López-Berges, et al.
Pageof 8

Showing results (21-30 of 72) with videos related to

Sort By:
Pageof 8
Hematological Oncology|September 29, 2006
Pegylated liposomal doxorubicin, melphalan and prednisone therapy for elderly patients with multiple myelomaR García-Sanz, J M Hernández, A Sureda, et al.
Clinical Biochemistry|October 6, 2000
Status of methylation of p16 gene in multiple myeloma: a comparative study of three methods for its detectionM V Mateos, M González, A Balanzategui, et al.
Leukemia|December 20, 2017
Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyondC S Chim, S K Kumar, R Z Orlowski, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Inverse Probability of Censoring Weighted Analysis to Adjust the Treatment Effect on Overall Survival for Subsequent Therapy: A Case Study in a Clinical Trial in Multiple MyelomaP Thilakarathne, A Palumbo, J Diels, et al.
Leukemia|March 8, 2019
Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyondC S Chim, S K Kumar, R Z Orlowski, et al.
Haematologica|June 15, 1999
Hematopoietic damage prior to PBSCT and its influence on hematopoietic recoveryM C del Cañizo, N Lopez, L Vazquez, et al.
Thrombosis Research|September 29, 2006
Hyperhomocysteinemia is a risk factor of recurrent coronary event in young patients irrespective to the MTHFR C677T polymorphismJ R Gonzalez-Porras, F Martin-Herrero, R Garcia-Sanz, et al.
Leukemia|July 30, 2002
Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantationJ A Pérez-Simón, D Caballero, M Diez-Campelo, et al.
Bone Marrow Transplantation|March 14, 2003
Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioningD Valcárcel, R Martino, D Caballero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 1998
Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemiaJ Ciudad, J F San Miguel, M C López-Berges, et al.
Pageof 8